ZHUHAI, China, March 15, 2024 /PRNewswire/ -- On March 14, 2024, Biotheus Inc. (Biotheus), a clinical-stage biotech company focusing on the discovery and development of biologics for oncology and inflammatory diseases, and Hansoh Pharmaceutical Group Co., Ltd. (Hansoh Pharma,03692.HK), China's leading innovation-driven pharmaceutical company, jointly announced that the two parties will further expand their strategic collaboration, following their current partnership since 2022.

中国珠海，2024年3月15日/PRNewswire/--2024年3月14日，专注于肿瘤和炎症性疾病生物制剂发现和开发的临床阶段生物技术公司Biotheus Inc.（Biotheus）和中国领先的创新驱动型制药公司Hansoh Pharmaceutical Group Co.，Ltd.（Hansoh Pharma，03692.HK），联合宣布，自2022年以来，双方将进一步扩大战略合作。

Biotheus will grant Hansoh Pharma a license to use the proprietary anti-EGFR/cMet bispecific antibody PM1080/HS-20117 independently developed by Biotheus for the development of antibody-drug conjugates products (ADC Product)..

Biotheus将授予Hansoh Pharma使用由Biotheus独立开发的专有抗EGFR/cMet双特异性抗体PM1080/HS-20117开发抗体-药物偶联物产品（ADC产品）的许可证。。

Under the terms of the agreement, Hansoh Pharma will obtain exclusive worldwide rights from Biotheus to use PM1080/HS-20117 for the development, production, and commercialization of ADC Product, with the right of sublicense. Biotheus will be eligible to receive up to 5 billion RMB in upfront and success-based milestones for ADC Product, as well as tiered royalties based on global net sales from Hansoh Pharma..

根据协议条款，汉索制药将获得Biotheus的全球独家使用权，使用PM1080/HS-20117进行ADC产品的开发，生产和商业化，并有权获得分许可。Biotheus将有资格获得高达50亿元人民币的ADC产品前期和基于成功的里程碑，以及基于Hansoh Pharma全球净销售额的分层版税。。

PM1080/HS-20117 is a 1+1 heterodimeric structure of EGFR/cMet bispecific antibody, which can inhibit the growth and survival of tumors by specifically targeting the tumor antigens EGFR and cMet, and is currently in phase I clinical trials.

PM1080/HS-20117是EGFR/cMet双特异性抗体的1+1异二聚体结构，可通过特异性靶向肿瘤抗原EGFR和cMet来抑制肿瘤的生长和存活，目前正在进行I期临床试验。

'This is the second collaboration between Hansoh and Biotheus. We really appreciate Hansoh's confidence in the potential of PM1080', said Mr. Xiaolin Liu, Co-founder, Chairman and Chief Executive Officer of Biotheus. 'Bispecific ADCs have a potential advantage for better tumor enrichment, overall efficacy and safety.

“这是Hansoh和Biotheus之间的第二次合作。Biotheus联合创始人、董事长兼首席执行官刘晓林表示：“我们非常感谢Hansoh对PM1080潜力的信心。”双特异性ADC具有更好的肿瘤富集，总体疗效和安全性的潜在优势。

Hansoh develops an outstanding ADC platform, and this collaboration will facilitate the synergy between Hansoh's ADC expertise and Biotheus' antibody capabilities. Through this collaboration, we hope to develop a novel EGFR/cMet bispecific ADC with better efficacy and safety for cancer patients worldwide.'.

Hansoh开发了一个出色的ADC平台，这种合作将促进Hansoh的ADC专业知识与Biotheus的抗体能力之间的协同作用。通过这次合作，我们希望开发一种新型EGFR/cMet双特异性ADC，对全球癌症患者具有更好的疗效和安全性。”。

'We are delighted to expand our partnership with Biotheus.' Said Ms Eliza Sun, Executive Director of the Board at Hansoh. 'This collaboration combines Hansoh's proprietary ADC Platform technology with Biotheus' novel bispecific antibody. We hope this new approach will further increase the clinical benefit in patients with NSCLC or other solid tumors.

“我们很高兴扩大与比奥修斯的合作关系。”汉莎百货董事会执行董事伊丽莎·孙女士说该合作将Hansoh专有的ADC平台技术与Biotheus的新型双特异性抗体相结合。我们希望这种新方法将进一步提高NSCLC或其他实体瘤患者的临床获益。

We are confident in our ability to offer transformative treatment options to cancer patients in China and worldwide. This is made possible through our extensive experience in clinical development, exceptional commercialization efforts, and external partnerships.'.

我们有信心为中国和世界各地的癌症患者提供变革性的治疗选择。这是通过我们在临床开发，非凡的商业化努力和外部合作伙伴关系方面的丰富经验而实现的。”。

About Biotheus Inc.

关于Biotheus Inc。

Biotheus is a clinical-stage biotech company dedicated to the discovery, development, and delivery of novel antibodies to address the unmet medical needs of patients with oncology and inflammatory diseases worldwide. Since its inception, Biotheus has established several innovative platforms for antibody discovery.

Biotheus是一家临床阶段的生物技术公司，致力于发现，开发和提供新型抗体，以满足全球肿瘤和炎症性疾病患者未满足的医疗需求。自成立以来，Biotheus为抗体发现建立了几个创新平台。

With an experienced R&D team, Biotheus has built a differentiated product pipeline with programs at various stages..

Biotheus拥有一支经验丰富的研发团队，建立了一条差异化的产品线，在各个阶段都有项目。。

For more information, please visit www.biotheus.com .

有关更多信息，请访问www.biotheus.com。

About Hansoh Pharma

关于Hansoh Pharma

Hansoh Pharma is a leading pharmaceutical company in Greater China driven by innovation. It is committed to the treatment of major diseases in the areas of oncology, anti-infections, CNS diseases, metabolic diseases, as well as autoimmune diseases, and is dedicated to improving human health through continuous innovation.

汉寿制药是一家在创新驱动下的大中华区领先的制药公司。它致力于治疗肿瘤学、抗感染、中枢神经系统疾病、代谢性疾病以及自身免疫性疾病等领域的重大疾病，并致力于通过不断创新改善人类健康。

Hansoh Pharma has been ranked among the top 100 global pharmaceutical companies and the top 3 best industrial enterprises in China in terms of pharmaceutical R&D pipeline for several years, and is a national key high-tech enterprise and a national technology innovation demonstration enterprise. Hansoh Pharma was listed on the Stock Exchange of Hong Kong in June, 2019 (stock code: 03692.HK)..

汉寿制药多年来一直跻身于全球制药企业百强和中国医药研发管道最佳工业企业前三名，是国家重点高新技术企业和国家技术创新示范企业。汉寿制药于2019年6月在香港联合交易所上市（股票代码：03692.HK）。。

For more information, please visit www.hspharm.com .

有关更多信息，请访问www.hspharm.com。

SOURCE Biotheus Inc.

SOURCE Biotheus公司。